GW501516 (also known as GW-501,516, GW1516, GSK-516, cardarine, and on the black market as endurobol) is a PPARδ receptor agonist that was invented in a collaboration between Ligand Pharmaceuticals and GlaxoSmithKline in the 1990s. It entered into clinical development as a drug candidate for metabolic and cardiovascular diseases, but was abandoned in 2007 because animal testing showed that the drug caused cancer to develop rapidly in several organs.
{{Drugbox | Verifiedfields = changed | verifiedrevid = 458657924 | IUPAC_name = {2-methyl-4-[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}methyl)sulfanyl]-2-methylphenoxy}acetic acid | image = GW501,516.svg | image_class = skin-invert-image | width = 270
| tradename = | legal_AU = Scheduled as illegal from June 2018 | legal_US = unscheduled | legal_UK = unscheduled | routes_of_administration = By mouth | pregnancy_category = N/A
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).